X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

How the rebate rule would help reduce patients’ out-of-pocket costs

By Tom Wilbur  |    June 3, 2019
The Department of Health and Human Services recently proposed a rule that would encourage using discounts negotiated between biopharmaceutical manufacturers and Part D plans to reduce patients’...   Read More

New study finds hospitals continue to push patients to costlier outpatient settings

By Holly Campbell  |    May 13, 2019
A new study from the Health Care Cost Institute found that, for commercially insured patients, almost 50 percent of medicines administered by physicians, including treatments for diseases like...   Read More

4 Things to know about the IQVIA “Medicine Use and Spending” report

By Holly Campbell  |    May 9, 2019
Today, IQVIA released its Medicine Use and Spending in the U.S. – A Review of 2018 and Outlook to 2023 report – highlighting the drivers behind medicine price and spending trends, patient...   Read More

Six policy solutions to help patients afford their insulin

By Holly Campbell  |    April 9, 2019
Dramatic improvements in how we treat diabetes have transformed the lives of patients, but too many struggle to afford their insulin and other medicines at the pharmacy counter. Due to...   Read More

PhRMA comments on OIG proposed rule to reform the rebate system

By Holly Campbell  |    April 8, 2019
Today, PhRMA submitted comments on the Department of Health & Human Services (HHS) Office of Inspector General (OIG) proposed rule, “Removal of Safe Harbor Protection for Rebates Involving...   Read More

340B continues to drive shift in site of care for physician-administered medicines to more expensive hospital settings

By Nicole Longo  |    April 5, 2019
Is 340B benefiting the vulnerable, uninsured patients it was designed to help? Evidence continues to show otherwise. An updated analysis from Berkeley Research Group (BRG) is the latest to build...   Read More

Five key facts about the market for insulins

By Holly Campbell  |    April 1, 2019
A century ago, patients were treated with animal insulins. Today, biopharmaceutical companies produce insulins that operate at the molecular level, more closely resembling insulin released...   Read More

OIG proposed rule could help strengthen the Part D market

By Holly Campbell  |    March 28, 2019
Patients should share in the $166B in rebates and discounts biopharmaceutical companies pay to insurance companies, the government, pharmacy benefit managers and other entities in the supply chain...   Read More

Rebate rule would help ensure seniors with diabetes don’t pay more for their medicine than their insurer

By Holly Campbell  |    March 25, 2019
Misaligned incentives in Medicare Part D are increasing costs for seniors with diabetes. While insurers negotiate larger and larger rebates with biopharmaceutical companies each year, seniors...   Read More

The PBM story you haven’t heard: Hidden fees quadrupled in two years

By Robert Zirkelbach  |    March 20, 2019
In the ongoing conversation around the role of pharmacy benefit managers (PBMs) in the supply chain, a new report further illuminates incentives that tie PBM revenue to higher list prices for...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates